Amgen rips off its $10B M&A cap, looking for deals “large and small”
You can put Amgen $AMGN on the list of biotech’s big game hunters.
In their quarterly meeting with analysts Thursday, Amgen CEO Bob Bradway said his $40 billion cache of cash gives him the flexibility to take a hard look at a variety of acquisitions this year, big and small.
For some time, Amgen set a $10 billion cap on deals, which is about what it paid for Onyx. This time? There isn’t a cap.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
